Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SyB C-0501 (Oral Bendamustine) in Advanced Solid Tumors
NCT03604679Phase 1Completed
- Sponsor
- SymBio Pharmaceuticals
- Start
- May 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bendamustine in solid tumor (advanced stage), breast cancer and small cell lung cancer (SCLC), sponsored by SymBio Pharmaceuticals. Primary endpoints: Dose-Limiting Toxicity and Adverse Events at 2 years. Started May 2018; status: completed.
02
Drugs
bendamustine
03
Conditions
solid tumor (advanced stage)breast cancersmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03604679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03604679.